HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chamberlain, M. C. Articles by Groshen, S. Search for Related Content PubMed PubMed Citation Articles by Chamberlain, M. C. Articles by Groshen, S. Related Collections All Clinical trials All Oncology Primary brain tumor Chemotherapy-tumor Clinical trials Observational study (Cohort, Case control)

Temozolomide for treatment-resistant recurrent meningioma

From the Departments of Neurology (Dr. Chamberlain) and Preventive Medicine (Dr. Groshen, D.D. Tsao-Wei), USC/Norris Cancer Center, Los Angeles, CA.

Address correspondence and reprint requests to Dr. M.C. Chamberlain, Department of Neurology, USC/Norris Cancer Center, 1441 Eastlake Ave., Suite 3459, Los Angeles, CA 90033-0804; e-mail: chamberl{at}usc.edu

A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma. All patients had previously been treated with surgery and involved-field radiotherapy; however, no patient had prior chemotherapy. TMZ was administered orally for 42 consecutive days every 10 weeks. Grade 3 or greater TMZ-related toxicity included anemia (25%), fatigue (18.7%), neutropenia (37.5%), seizures (6.3%), and thrombocytopenia (18.7%). No patient demonstrated a neuroradiographic complete or partial response. Time to tumor progression ranged from 2.5 to 5.0 months (median 5.0 months); survival ranged from 4 to 9 months (median 7.5 months).

Received September 12, 2003. Accepted in final form December 1, 2003.

This article has been cited by other articles:

				M. C. Chamberlain, M. J. Glantz, and C. E. Fadul Recurrent meningioma: Salvage therapy with long-acting somatostatin analogue Neurology, September 4, 2007; 69(10): 969 - 973. [Abstract] [Full Text] [PDF]